China Universal Asset Management Co. Ltd. Makes New Investment in 10x Genomics, Inc. (NASDAQ:TXG)

China Universal Asset Management Co. Ltd. acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 22,687 shares of the company’s stock, valued at approximately $326,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC increased its holdings in 10x Genomics by 2.7% during the 3rd quarter. FMR LLC now owns 13,367,979 shares of the company’s stock worth $301,849,000 after purchasing an additional 357,470 shares in the last quarter. ARK Investment Management LLC grew its holdings in 10x Genomics by 15.4% during the third quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock worth $242,743,000 after buying an additional 1,436,582 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in 10x Genomics by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company’s stock valued at $143,907,000 after buying an additional 230,145 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in 10x Genomics during the 4th quarter valued at $26,308,000. Finally, Geode Capital Management LLC boosted its holdings in 10x Genomics by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock worth $41,009,000 after acquiring an additional 42,777 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on TXG shares. UBS Group dropped their price target on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. Morgan Stanley cut their target price on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Citigroup cut their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a research report on Wednesday, October 30th. Stephens reaffirmed an “overweight” rating and set a $30.00 target price on shares of 10x Genomics in a research report on Thursday, October 10th. Finally, Barclays cut their price target on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, 10x Genomics has an average rating of “Moderate Buy” and an average price target of $23.86.

10x Genomics Stock Performance

Shares of NASDAQ TXG opened at $15.00 on Monday. 10x Genomics, Inc. has a fifty-two week low of $12.95 and a fifty-two week high of $51.22. The stock has a market cap of $1.82 billion, a PE ratio of -9.80 and a beta of 1.83. The stock has a fifty day moving average of $15.16 and a 200-day moving average of $17.74.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.